Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution.
about
Aptamers: A Feasible Technology in Cancer ImmunotherapyMolecular Selection, Modification and Development of Therapeutic Oligonucleotide AptamersFit for the Eye: Aptamers in Ocular DisordersVascular endothelial growth factor as an anti-angiogenic target for cancer therapyPharmacokinetics and Toxicity in Rats and Monkeys of coDbait: A Therapeutic Double-stranded DNA Oligonucleotide Conjugated to CholesterolAptamers: from bench side research towards patented molecules with therapeutic applications.Induced protein degradation: an emerging drug discovery paradigm.Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells5'-Cholesteryl-phosphorothioate oligodeoxynucleotides: potent inhibition of methotrexate transport and antagonism of methotrexate toxicity in cells containing the reduced-folate carrier.Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis.Perfluoroalkylchain conjugation as a new tactic for enhancing cell permeability of peptide nucleic acids (PNAs) via reducing the nanoparticle size.Antisense imaging of gene expression in the brain in vivoAntisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.Encapsulation of oligonucleotides in stealth Me.PEG-PLA50 nanoparticles by complexation with structured oligopeptides.Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacyInhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase.Pharmacokinetics of a Cholesterol-conjugated Aptamer Against the Hepatitis C Virus (HCV) NS5B Protein.Bioconjugation of oligonucleotides for treating liver fibrosis.Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.Use of RNA in drug design.Selection of a novel DNA thioaptamer against HER2 structure.Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation.Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging.Aptamer and its applications in neurodegenerative diseases.Antisense oligodeoxynucleotides as clinical therapeutic agents.Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes.Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo.
P2860
Q26740303-0A63BA55-1223-4E16-8B72-FA0676D17868Q26765458-7E6A6EDF-B005-4D61-A4CC-FBF9F6A4215FQ28828283-C698E057-2D51-4B34-A7FB-C1E82D35F059Q30455612-B45E7022-F4B3-4159-8D7C-15C1EF609F06Q30523973-EB8B4DD1-DDC9-4D2E-8EC3-41D00521DBB5Q33512089-0CFFC69C-5DDD-45B7-8AA7-801263FAD0A5Q34545841-C1DE2E34-7CBF-4288-987C-4901069C7E09Q34558137-94B7D894-32A1-43AF-BA77-F7C6368C9354Q34772710-DBC63DC7-35FE-488B-A11E-7C15470F49AAQ35668979-E9AB3BED-E78A-4A6F-8DE5-D3D28EF71FE6Q35831633-F56188BD-74F3-491C-8A1C-A6D978938046Q35853732-526CC3BA-C72A-4993-A656-294F2E354EE1Q35856548-C4710CA5-3471-4E80-B7DB-1B7AA3808340Q35899304-31D616FD-FDE5-473F-B100-D9B239BE72FAQ36087670-428E1833-A5C3-490C-8933-9509A17F1FE0Q36911663-B7FEFDCC-DA4C-4EB4-B9D7-B77A6FC0AB8FQ36939736-33DDB46D-02C4-4A85-92E1-FB2E6DD5EA28Q37043515-2A8C5E01-2EFE-4477-8874-1D4D24CD8946Q37586838-68EA2CCE-916A-4896-B423-8C180C3D5217Q38089160-5E695C66-D7BF-4767-B0B7-E72FCFDDFF6FQ38298656-27A50FF7-77CA-4555-B53A-CD75BCD84AEBQ38310396-A59008A2-8B24-4AED-8541-06C2754A7A0DQ38548184-1A4C217F-DA5F-4AEB-B8AF-C9379B7879E4Q38937721-611441CC-2914-4C41-AA8C-26E0694332A3Q40968139-85A5EB6D-63C2-461E-834E-8869F011BEE5Q41573492-417FE8E8-B2C2-4A71-9561-C7A0B78E379CQ48827568-AC949BAC-5DDA-45A7-A067-531476D9D5C8
P2860
Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Association of antisense oligo ...... ifies the tissue distribution.
@ast
Association of antisense oligo ...... ifies the tissue distribution.
@en
type
label
Association of antisense oligo ...... ifies the tissue distribution.
@ast
Association of antisense oligo ...... ifies the tissue distribution.
@en
prefLabel
Association of antisense oligo ...... ifies the tissue distribution.
@ast
Association of antisense oligo ...... ifies the tissue distribution.
@en
P2093
P2860
P356
P1476
Association of antisense oligo ...... ifies the tissue distribution.
@en
P2093
de Falco S
de Smidt PC
van Berkel TJ
P2860
P304
P356
10.1093/NAR/19.17.4695
P407
P577
1991-09-01T00:00:00Z